Few companies in the biotech industry have performed better in the past two years than Summit Therapeutics (NASDAQ: SMMT).

We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Summit Therapeutics has soared due to hopes around its cancer drug candidate, ivonescimab. It outperformed Keytruda in a phase 3 trial for treating advanced non-small cell lung cancer. Investors ...

Shares of Summit Therapeutics (NASDAQ: SMMT) had jumped 14.3% at 11:31 a.m. ET on Tuesday. The nice gain came after reports that H.C. Wainwright analyst Mitchell Kapoor maintained a "buy" rating ...

Shares of Summit Therapeutics Inc. (NASDAQ:SMMT – Get Free Report) have been given a consensus recommendation of “Moderate ...

Summit Therapeutics Inc. (NASDAQ:SMMT – Free Report) by 13.6% during the 4th quarter, according to the company in its most ...

Summit Therapeutics' drug Ivonescimab posted positive results in not one but two phase 3 trials during 2024. It also received "fast track" status from the FDA. Despite its massive 2024 gains ...

In this article, we are going to take a look at where Summit Therapeutics Inc. (NASDAQ:SMMT) stands against the other healthcare stocks. McKinsey reported that, since 2019, the US healthcare ...

Shares of biotech Summit Therapeutics (NASDAQ: SMMT) skyrocketed 583.7% in 2024, according to data from S&P Global Market Intelligence. Summit was an early-stage biotechnology stock heading into ...